![](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/play-icon.png\"\/){kind=icon}
Listen to this article<\/p>\n Listen to this article<\/p>\n
Summary:<\/p>\n
Hims<\/a> launched a $49 compounded oral GLP-1 weight-loss pill in the US, significantly cheaper than Novo Nordisk<\/a>\u2018s $199 Wegovy<\/a>. NEW YORK \u2014 Online telehealth company Hims and Hers Health on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk\u2019s new Wegovy weight-loss pill in a move that expands sales to many Americans but could undercut Novo\u2019s and Eli Lilly<\/a>\u2018s plans for the consumer market.\n<\/p>\n The news touched off a swift reaction on Wall Street as investors sold off Novo and Lilly shares, and the Danish drugmaker promised a legal challenge to the move by Hims.<\/p>\n Novo shares fell 8.6%, while Lilly was off 6%.\n<\/p>\n Hims said the $49 one-month introductory price will rise to $99 per month for those who purchase a five-month plan and pay upfront. The monthly price is higher for a three-month subscription. Novo plans to charge $199 for its oral Wegovy, with no subscription.\n<\/p>\n The announcement comes as Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its full-year forecast. Novo shares on Thursday hit their lowest level since July 2021.<\/p>\n Novo spokeswoman Ambre James-Brown said only the Danish drugmaker can sell the Wegovy pill with its unique technology that allows absorption of the medicine.\n<\/p>\n \u201cThe action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework,\u201d she said.\n<\/p>\n Hims had been allowed by the U.S. Food and Drug Administration to sell versions of Novo\u2019s GLP-1 injectible drugs while the branded medicines were in short supply. Since then, it has made \u201cpersonalized\u201d copies of the branded drugs at different doses or regimens than those available from Novo and other drug companies.\n<\/p>\n \u201cThe status quo for months now has been a compounder can create a copycat version of a branded drug, so long as they make some kind of minor tweak that they believe or they argue benefits specific patient groups,\u201d said TD Cowen analyst Michael Nedelcovych.\n<\/p>\n Hims makes case for choice\n<\/p>\n
\nNovo Nordisk announced plans for legal and regulatory action against Hims, citing patent and safety concerns.
\nHims tailors its treatment to patient needs, offering an oral alternative to injectable GLP-1 drugs like Wegovy and Ozempic.<\/p>\n